Medicines labeled for the same conditions

Alternatives to trastuzumab-strf

12 other medicines are given the same way (intravenous) and in the same FDA class as trastuzumab-strf or labeled mainly for the same use (breast cancer); 3 are in its class, her2/neu receptor antagonists: trastuzumab, margetuximab and pertuzumab; the others include 3 microtubule inhibitors, 1 nucleoside metabolic inhibitor and 1 estrogen receptor antagonist (FDA labels read October 8, 2026).

Which medicines are labeled for the same conditions as trastuzumab-strf?

Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.

Medicine and FDA class	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Boxed warning	Shortage
Trastuzumab-strfher2/neu receptor antagonist	this medicine	none listed	n/a	Yes	No current entry
Trastuzumabher2/neu receptor antagonist · same class	Breast cancer	none listed	n/a	Yes	No current entry
Margetuximabher2/neu receptor antagonist · same class	Breast cancer	none listed	n/a	Yes	No current entry
Pertuzumabher2/neu receptor antagonist · same class	Breast cancer	none listed	n/a	Yes	No current entry
Docetaxelmicrotubule inhibitor	Breast cancer	14 labelers	n/a	Yes	A presentation being discontinued
Paclitaxelmicrotubule inhibitor	Breast cancer	20 labelers	n/a	Yes	No current entry
Gemcitabinenucleoside metabolic inhibitor	Breast cancer	10 labelers	n/a	No	No current entry
Eribulinmicrotubule inhibitor	Breast cancer	14 labelers	n/a	No	No current entry
Trastuzumab emtansine	Breast cancer	none listed	n/a	Yes	No current entry
Fulvestrantestrogen receptor antagonist	Breast cancer	1 labeler	n/a	No	A presentation being discontinued
Ixabepilone	Breast cancer	none listed	n/a	Yes	No current entry
Sacituzumab govitecan	Breast cancer	none listed	n/a	Yes	No current entry
Trastuzumab deruxtecan	Breast cancer	none listed	n/a	Yes	No current entry

Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)

What next?

Trastuzumab-strf: the full record: label, generics, price, shortages, recalls